9 completed, 2 withdrawn, 1 active not recruiting. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Cytomegalovirus Infection: new trials by email Literature Review of Cytomegalovirus Infection trials Research Report on Cytomegalovirus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Withdrawn | ModernaTX, Inc. | 2024-02-08 | 2024-03-15 | |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Active not recruiting | ModernaTX, Inc. | 84 | 2023-04-05 | 2026-08-10 |
| A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection BCV - Adenovirus Infections, Cytomegalovirus Infection | Phase 2 | Completed | SymBio Pharmaceuticals | 53 | 2021-08-16 | 2026-08-11 |
| A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine mRNA-1647 - Cytomegalovirus Infection | Phase 2 | Completed | ModernaTX, Inc. | 135 | 2021-06-18 | 2026-02-02 |
| Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 2 | Completed | ModernaTX, Inc. | 315 | 2020-01-09 | 2026-05-05 |
| Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation virus-specific T-Cells - Cytomegalovirus Infection, Adenovirus Infection | Phase 1 / Phase 2 | Withdrawn | St. Anna Kinderkrebsforschung | 2016-08-03 | 2019-05-09 | |
| Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss Placebo, Valganciclovir - Cytomegalovirus Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 54 | 2015-02-24 | 2024-10-16 |
| Alternate Donor Study of Pre-Emptive Cellular Therapy CMV-specific T-cells, single infusion following single positive CMV PCR result - Cytomegalovirus Infection | Phase 2 | Completed | Cell Medica Ltd | 52 | 2010-10-01 | 2018-01-25 |
| Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Brincidofovir, Placebo - Cytomegalovirus Infection | Phase 2 | Completed | Jazz Pharmaceuticals | 239 | 2009-10-01 | 2021-07-16 |
| Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection HCMV-specific hyperimmune globulin (Cytotect®), Isotonic solution of sodium chloride (placebo) - Cytomegalovirus Infection | Phase 2 / Phase 3 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 124 | 2009-06-01 | 2011-12-08 |
| TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Valganciclovir - Cytomegalovirus Infection | Phase 2 | Completed | PETHEMA Foundation | 132 | 2005-11-01 | 2009-09-18 |
| Maribavir for Prevention of CMV After Stem Cell Transplants Maribavir, Placebo - Cytomegalovirus Infection | Phase 2 | Completed | Shire | 111 | 2004-10-28 | 2021-05-13 |
Cytomegalovirus Infections (12) · DNA Virus Infections (4) · Virus Diseases (4) · Adenoviridae Infections (2) · Herpes Simplex (2) · Hearing Loss (1)
Herpesviridae Infections (12) · Infections (12) · DNA Virus Infections (8) · Virus Diseases (8) · Skin Diseases (2) · Skin Diseases, Infectious (2) · Skin Diseases, Viral (2) · Skin and Connective Tissue Diseases (2) · Ear Diseases (1) · Hearing Disorders (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Otorhinolaryngologic Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Sensation Disorders (1)
mRNA-1647 cytomegalovirus vaccine (4) · Valganciclovir (2) · brincidofovir (1) · cytomegalovirus-specific hyperimmune globulin (1) · maribavir (1)
ModernaTX, Inc. (4) · Cell Medica Ltd (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Jazz Pharmaceuticals (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · PETHEMA Foundation (1) · Shire (1) · St. Anna Kinderkrebsforschung (1) · SymBio Pharmaceuticals (1)
United States (7) · United Kingdom (2) · Austria (1) · Italy (1) · Spain (1)
Karl S Peggs (1) · Maria Grazia Revello, MD (1) · Susanne Matthes, MD (1)
PMID 18285548, PMID 24066743, PMID 24693891, PMID 27851688, PMID 38190492, PMID 38309519
2005 (1)